Ben Venue began distributing the drug to hospitals, oncology clinics and pediatric facilities yesterday. The goal is to satisfy near-term patient needs while other companies increase production of the drug.
The supply Ben Venue is releasing was produced before the company voluntarily suspended manufacturing in November 2011 to attend to manufacturing-related issues identified in FDA inspections, according to the release.
Related Articles on Drug Shortages:
Senator, Oncology Groups Urge Pharma to Boost Production of Pediatric Cancer Drug
Senators Klobuchar and Collins Discuss Drug Shortages on Senate Floor
Institute for Safe Medication Practices Questions Medication Storage Rules